* EU secures at least 300 mln doses of AstraZeneca vaccine
* Move could weaken WHO-led initiative for global approach
* EU countries could buy additional 100 million doses
* AstraZeneca says vaccine sold at no profit during pandemic
(adds AstraZeneca comment, impact on WHO, details)
By Francesco Guarascio
BRUSSELS, Aug 14 (Reuters) - The European Union has agreed
to buy at least 300 million doses of AstraZeneca's
potential COVID-19 vaccine in its first such advance purchase
deal, which could weaken plans led by the World Health
Organisation for a global approach.
The European Commission, which is negotiating on behalf of
all 27 EU member states, said the deal included an option to
purchase 100 million additional doses from the British drugmaker
should its vaccine prove safe and effective.
The EU's bilateral deal mirrors moves by the United States
and other wealthy states, some of which are critical of the
WHO's initiative, and further reduces the potentially available
stock in the race to secure effective COVID-19 vaccines.
The EU agreement follows an initial deal with AstraZeneca
reached in June by Europe's Inclusive Vaccines Alliance (IVA), a
group formed by France, Germany, Italy and the Netherlands to
secure vaccine doses for all member states.
The Commission did not disclose the terms of the new deal
and declined to say whether it had replaced the IVA's.
"This new agreement will give all EU member states the
option to access the vaccine in an equitable manner at no profit
during the pandemic," AstraZeneca said in a statement.
The EU executive said its deals are aimed at financing part
of the upfront costs to develop vaccines. The funding would be
partial down-payments to secure the shots, but actual purchases
would be decided at a later stage by each EU state.
The EU said over the past two weeks it was in advanced talks
with Johnson & Johnson and Sanofi for their
vaccines under development .
It is also in talks with Pfizer, Moderna
and CureVac to buy upfront their potential COVID-19 vaccines, EU
officials told Reuters in July.
BLOW TO WHO?
The EU move could make more difficult efforts led by the WHO
and GAVI, a global alliance for vaccines, to buy shots on behalf
of rich and developing countries with a separate scheme.
The Commission has urged EU states to shun the WHO-led
initiative because it sees it as too expensive and slow, EU
officials told Reuters in July.
Now the Commission is openly saying that vaccines bought
from AstraZeneca, and from other vaccine makers, could be
donated to poorer states, effectively taking on the very task
that the WHO is pursuing with the so-called ACT-Accelerator Hub.
Brussels has publicly said that its purchasing scheme is
complementary to the WHO's, but in private told EU states that
there may be legal issues if they joined the WHO programme.
(Reporting by Francesco Guarascio; Editing by Jan Harvey, Jason
Neely and Alexander Smith)
Astrazeneca (AZN)